Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balic Marija, Tang Gong, Rastogi Priya, Young Gregory, Wallace Matthew, Acosta Joshua, Schneeweiss Andreas, Hilton Christie J, Freeman Tanner J, Li Jiahe, Denkert Carsten, Reinisch Mattea, Palomares Melanie R, Arrick Bradley A, Petitt Matthew, Maley Sai K, Hassan Saima, Murali Sujatha, Boileau Jean-François, Boudreau Dominique, Polewski Peter J, Mashru Sandeep, Hargis Jeffrey B, Mortimer Joanne, Thirlwell Michael, Sikov William, Tan Antoinette R, Garces Jorge, Costa Gina, LoBello Janine, Mouta João, Darbonne Walter C, Baehner Frederick L, Mamounas Eleftherios P, Wolmark Norman, Loibl Sibylle, Geyer Charles E
Аннотация
MATERIALS AND METHODS: This substudy included NSABP B-59 patients with serial blood collections before NAT (baseline), after NAT before surgery, 3-6 weeks postsurgery, and 12 and 24 months after random assignment. The primary objective was to evaluate the association between ctDNA status postsurgery with distant recurrence-free interval, defined from the date of surgery to first distant metastasis or death from breast cancer. The median follow-up for the primary end point was 37 months.
RESULTS: At baseline, ctDNA was detected in 153 of 160 patients (96%). Among 147 patients with ctDNA assessment postsurgery, ctDNA was detected in nine (6%). Distant recurrence occurred in seven of nine (77.8%) patients with ctDNA-positive status postsurgery, compared with seven of 138 (5%) with ctDNA-negative status postsurgery (log-rank P < 1E-16; hazard ratio, 30.3 [95% CI, 10.4 to 88.7]). Among patients with residual invasive disease after NAT and surgery, five of 42 (11.9%) with negative ctDNA status developed distant recurrence versus six of seven (85.7%) in those with positive ctDNA status.
CONCLUSION: The tumor-informed MRD assay demonstrated high baseline ctDNA prevalence, marked clearance with NAT, and strong prognostic utility of post-NAT and postsurgery ctDNA-positive status for distant recurrence in early TNBC.